The drugmaker is scouting for a replacement for its CEO, Kenneth Frazier.
Sun Pharma hit with Form 483 for Halol facility
The drugmaker said it has received four observations from the U.S. FDA for its Halol facility in Gujarat.
Just days after receiving approval in Japan, Daiichi Sankyo said the U.S. FDA will not approve its drug, quizartinib.
Why the industry is forming bonds with CBD
The drugmaker admitted that studies showed its rheumatoid arthritis medication Enbrel could potentially reduce the risk of Alzheimer’s by 64 percent.
Don't miss your Daily Dose. Sign up to get news like this delivered right to your inbox.